Seres Therapeutics (MCRB) Misses Q2 EPS by 17c

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of $0.36, $0.17 worse than the analyst estimate of $0.53. Revenue for the quarter came in at $126.47 million versus the consensus estimate of $125.67 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• NVE Corporation names new CEO and expands board to seven members
• Pfizer lung cancer drug misses survival goal in Phase 3 trial